Drug Trial Radar · NCT01081769
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
Last checked: Nov 19, 2026Latest source record: Feb 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
769
Actual
Start
Feb 2010
Primary completion
Feb 2013
Study completion Feb 2013
Sponsor
- Lead sponsor
- Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.
Conditions
- Schizophrenia
Interventions
paliperidone palmitate injectionDrug
injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
oral antipsychoticsDrug
daily treatment according to local label for maximally 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Relapse EventTime frame: from baseline (Day 1 of core phase) up to maximally 24 months.
- Number of Participants With a Relapse EventTime frame: from baseline (Day 1 of core phase) up to maximally 24 months
Locations
94 sites in 25 countries. Site status is shown where the registry gives one.
Site not named
Vienna, Austria
Site not named
Bertrix, Belgium
Site not named
Ghent, Belgium
Site not named
Liège, Belgium
Site not named
Ostend, Belgium
Site not named
Burgas, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Radnevo, Bulgaria
Site not named
Zagreb, Croatia
Site not named
Brno, Czechia
Site not named
Litoměřice, Czechia
Site not named
Olomouc, Czechia
Site not named
Prague, Czechia
Site not named
Přerov, Czechia
Site not named
Alexandria, Egypt
Site not named
Cairo, Egypt
Site not named
Talinn, Estonia
Site not named
Tartu, Estonia
Site not named
Colombes, France
Site not named
La Seyne-sur-Mer, France
Site not named
Limoges, France
Site not named
Metz, France
Site not named
Paris, France
Site not named
Saint-Avé, France
Site not named
Berlin, Germany
Site not named
Bochum, Germany
Site not named
Mannheim, Germany
Site not named
München, Germany
Site not named
Thessalonikis, Greece
Site not named
Budapest, Hungary
Site not named
Kalocsa, Hungary
Site not named
Nagykálló, Hungary
Site not named
Sopron, Hungary
Site not named
Bat Yam, Israel
Site not named
Beer Yaakov, Israel
Site not named
Hod HaSharon, Israel
Site not named
Ramat Gan, Israel
Site not named
Tirat Hacarmel, Israel
Site not named
Amman, Jordan
Site not named
Šiauliai, Lithuania
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.